Key result
Cardiac autoantibodies may inform arrhythmic risk stratification and perturb cardiac excitability in myocarditis.
Why the study?
Arrhythmias in myocarditis and inflammatory cardiomyopathy have traditionally been attributed to structural substrates, whereas the direct pathogenic role of circulating cardiac autoantibodies in perturbing cardiac excitability and guiding risk stratification or immunomodulatory therapy remains an underexplored area with limited direct clinical evidence.
Does autoantibody testing and profiling improve arrhythmic risk stratification and help identify patients with myocarditis or inflammatory cardiomyopathy who may benefit from immunomodulatory or immunosuppressive strategies?
Does autoantibody testing and profiling improve arrhythmic risk stratification and help identify patients with myocarditis or inflammatory cardiomyopathy who may benefit from immunomodulatory or immunosuppressive strategies?
Answers are grounded in this paper and cite their sources.
This narrative review highlights the mechanistic and clinical links between circulating cardiac autoantibodies and arrhythmias in myocarditis, while noting that the utility of autoantibody-guided immunotherapy remains limited by a lack of randomized trials.
Myocarditis is an inflammatory disease that may be associated with severe acute and chronic complications, including progression to inflammatory cardiomyopathy, characterized by persistent inflammation, cardiac dysfunction, and adverse ventricular remodeling. Arrhythmias are major determinants of morbidity and mortality across this disease spectrum and have traditionally been attributed to structural substrates such as myocardial edema, necrosis, and fibrosis. However, as the role of the immune system in myocarditis is increasingly recognized, growing attention has been focused on immune-mediated mechanisms capable of directly perturbing cardiac excitability. Circulating cardiac autoantibodies are frequently detected in patients with myocarditis. Beyond their potential diagnostic value, specific autoantibody subsets have been hypothesized to exert pathogenic effects by targeting receptors, ion channels, contractile proteins, and intercalated disk components involved in impulse generation, conduction, repolarization, calcium handling, and myocardial structural integrity. This narrative review evaluates the mechanistic basis of autoimmune arrhythmias, the available preclinical and clinical evidence linking autoantibodies to atrial and ventricular arrhythmias, and the potential role of autoantibody profiling in refining arrhythmic risk stratification. Particular attention is given to distinguishing direct evidence obtained in patients with myocarditis and inflammatory cardiomyopathy from findings derived from other cardiac or systemic diseases and experimental models, whose applicability to myocardial inflammatory disorders remains uncertain. Finally, we critically evaluate whether autoantibody testing may help identify patients more likely to benefit from immunomodulatory or immunosuppressive strategies, while emphasizing the current limitations related to small observational cohorts and the lack of randomized trials evaluating antibody-guided treatment strategies with dedicated arrhythmic endpoints.
No takes yet. Share an insight, caveat, or question.
Marmai et al. (2026) conducted a review in Myocarditis and inflammatory cardiomyopathy. Circulating cardiac autoantibodies and autoantibody profiling was evaluated on Atrial and ventricular arrhythmias. Circulating cardiac autoantibodies may directly perturb cardiac excitability and inform arrhythmic risk stratification in myocarditis, though evidence from randomized trials is lacking.
Synapse has enriched 10 related papers. Consider them for comparative context: